The American Association of Gynecologic Laparoscopists (AAGL) has joined several other ob/gyn organizations to endorse the US Surgeon General's recommendation to suspend elective surgeries amidst the coronavirus (COVID-19) pandemic.
The American Association of Gynecologic Laparoscopists (AAGL) has joined several other ob/gyn organizations to endorse the US Surgeon General's recommendation to suspend elective surgeries amidst the coronavirus (COVID-19) pandemic. Other organizations supporting this recommendation include the American College of Obstetricians and Gynecologists (ACOG), the American Society of Reproductive Medicine (ASRM), the American Urogynecologic Society (AUGS), Society of Family Planning (SFP), Society of Gynecologic Oncology (SGO), Society of Gynecologic Surgeons (SGS) and Society for Maternal-Fetal Medicine (SMFM).
As the impact of the pandemic continues to intensify, the resources of the health care system, hospital systems, clinics, and communities will be further strained. The Surgeon General’s statement urging healthcare providers to suspend elective surgeries is part of a broader strategy to free up resources. AAGL notes that surgical procedures performed by ob/gyns are generally medically indicated procedures necessary for patient health and safety. However, in areas where COVID-19 is particularly prevalent or where there is already stress on the health care system, modifying surgical scheduling could help preserve resources.
The organization reiterates that the recommended suspension is for elective procedures only. Obstetric and gynecologic procedures for which a delay could negatively impact the patient’s health or pregnancy should not be delayed. However, it is also important to be cognizant of the unintended effects that COVID-19 cases and policies may have on a healthcare provider’s time, including limiting access to time-sensitive obstetric and gynecological procedures.
At this unusual time and with circumstances rapidly evolving, it is important for ob/gyns to stay updated on the most-up-to-date policies. AAGL recommends consulting the CDC’s Interim Guidance for Healthcare Facilities: Preparing for Community Transmission of COVID-19 in the United States.
Phase 2b safety data for Sildenafil Cream against FSAD reported
August 26th 2024In a recent study published in The Journal of Sexual Medicine, Sildenafil Cream, 3.6% was indicated as safe and well-tolerated for use against female sexual arousal disorder in healthy premenopausal women.
Read More
Contemporary OB/GYN Senior Editor Angie DeRosa gets insight on the current state of COVID-19 from Christina Han, MD, division director of maternal-fetal medicine at the University of California, Los Angeles, and member of its COVID-19 task force. Han is an active member of the Society for Maternal-Fetal Medicine and discusses the issues on behalf of SMFM.
Listen
Study: Pelvic floor dilator reduces pelvic floor muscle injury during vaginal delivery
August 6th 2024A new pilot study published in the International Urogynecology Journal found that Materna Medical’s Prep Device, a pelvic floor dilator, reduced full levator ani muscle avulsion during vaginal delivery in first-time mothers.
Read More
Similar success rates for synthetic and nonsynthetic slings in SUI treatment
July 31st 2024A study found that both synthetic and nonsynthetic slings show similar success rates for treating stress urinary incontinence in women, with synthetic slings demonstrating improved operative outcomes and reduced complications.
Read More
First hysterectomy using miniaturized MIRA Surgical System performed
July 30th 2024Virtual Incision Corporation has announced the successful performance of the first benign hysterectomy using their miniaturized robotic-assisted surgery device, MIRA, in a clinical trial assessing its safety and efficacy.
Read More